Chronic migraine (CM) is a severely disabling neurological condition characterized by episodes of pulsating unilateral or bilateral headache. The United States Food and Drug Administration (FDA) approved onabotulinumtoxinA (Botox ® ) for the prophylactic treatment of CM in 2010. It has been shown that onabotulinumtoxinA is effective in the reduction of headache frequency and severity in patients with CM. Treatment is well tolerated by the patients. This review reports on the history of botulinum neurotoxin (BoNT) in CM and presents the current clinical evidence for the use of onabotulinumtoxinA in the treatment of CM.
Introduction
Migraine is a common neurological disorder featuring recurrent attacks of headache. Typical migraine attacks last for 4-72 h and involve headaches of the following characteristics: pulsating quality, unilateral location, moderate or severe intensity and aggravation by routine physical activity. Attacks can be accompanied with nausea, vomiting, photophobia and phonophobia [Headache Classification Committee of the International Headache Society, 2013].
As stated by the International Headache Society (IHS) classification, migraine has two major subtypes: migraine without aura and migraine with aura. Aura symptoms are focal, neurological symptoms usually occurring prior to or sometimes during a migraine attack. They are fully reversible and last for 5-60 min. It is possible that patients suffer from migraine attacks both without and with aura.
More relevant to clinical practice is the distinction between episodic migraine (EM) and chronic migraine (CM). Although not mentioned in the IHS Classification, the term EM is quite common in scientific literature and among clinicians. It refers to patients, who suffer from migraine attacks, but miss the criteria for CM. CM originally described a migraine headache present on at least 15 days per month for more than 3 months. According to the 2nd edition of the IHS classification, the diagnosis of CM could only be applied in patients without medication overuse [Headache Classification Subcommittee of the IHS, 2004 ]. Because only very few patients met these strict criteria, the IHS revised its definition for CM. The new definition was published in 2006 [Olesen et al. 2006 ] and finally incorporated in the 3rd edition of the International Classification of Headache disorders in 2013. According to the revised criteria CM is currently defined as a headache occurring on at least 15 days per month for more than 3 months, with typical features of migraine on at least 8 days per month. Medication overuse no longer excludes the diagnosis of CM [Headache Classification Committee of the IHS, 2013].
Epidemiology
A review of international studies on the epidemiology of CM presents a wide range of prevalence figures [Natoli et al. 2010] . Depending on the definition used and the population studied these numbers range from 0% [Rasmussen et al. 1991] to 5.1% [Queiroz et al. 2006 ]. More recent studies using the current IHS definition report a prevalence of 0.91% in the US population [Buse et al. 2012 ] and 0.5% in the German population [Katsarava et al. 2011] . Several studies in the general population and in patients with CM show that women are more likely to be affected by CM than men Blumenfeld et al. 2010; Diener et al. 2007 ]. Adjusted prevalence increases for both women and men from adolescence to midlife and declines after the fifth decade of life. In the population subgroup with the highest adjusted prevalence of CM (women between age 40-49) 1.89% are affected by CM [Buse et al. 2012] .
In recent years, various studies investigated differences between episodic and chronic migraineurs. Compared with episodic migraineurs, patients with CM are at risk of a wide range of comorbid conditions such as asthma, chronic obstructive pulmonary disease, obesity, heart disease, stroke, depression and anxiety [Buse, 2010] . Due to the high frequency of migraine attacks, medication overuse is highly common among chronic migraineurs. Interventional studies in patients with CM found rates of 40.9% [Cernuda-Morollón et al. 2014 ] to 50.4% [Khalil et al. 2014] for medication overuse.
Socioeconomic status is reduced in patients with CM compared with those with less frequent headache. They have a lower annual income, are less likely to be employed part or full time and more likely to be occupationally disabled [Adams et al. 2015; Buse et al. 2010] . Patients with CM require more primary care visits, specialist visits, emergency room visits and are hospitalized more often. Unsurprisingly, CM has an enormous negative impact on quality of life Wang et al. 2013 ].
Management and pharmacologic treatment
Diagnosis of CM is based on the patient's history (including a headache diary) and neurological examination. In some patients, cerebral magnetic resonance imaging and lumbar puncture might be necessary in order to rule out secondary causes for headaches [Diener et al. 2015] .
The main goal in the treatment of CM is to reduce the impact of migraine on patients' lives. Therefore, it is necessary to keep migraine attacks as rare, short and as less-impairing as possible. Various nonpharmacological measures are useful to prevent migraine attacks: trigger avoidance (caffeine, alcohol, stress), dealing with risk factors (losing weight, modify response to stressors, getting sufficient sleep) [Schwedt, 2014] .
Pharmacological treatment of CM is based on two pillars: abortive treatment of acute migraine attacks and prophylactic treatment. The substances most commonly used for the abortion of migraine attacks are nonsteroidal anti-inflammatory drugs (NSAIDs) and triptanes. There is good clinical evidence, that both substance groups are effective in the abortive treatment of acute migraine attacks. On the other hand, it has been shown, that both NSAIDs and triptanes may lead to medication overuse headaches. Therefore, the challenge is to restrict migraine-abortive substances to the least amount necessary. This observation highlights the special importance of prophylactic treatment in patients with CM. Generally, prophylactic medication can be given as soon as the diagnosis of CM is established. The choice of which substance is applied should be made with regard to the patient's comorbidities [Straube et al. 2012] .
Because most clinical studies focused on EM, studies on prophylactic treatment of CM are scarce. The substances, which have been studied in patients with CM specifically, are: valproate [Yurekli et al. 2008] , amitriptyline [Couch and Amitriptyline versus Placebo Study Group, 2011], gabapentin [Spira et al. 2003 ], topiramate [Diener et al. 2007; Silberstein et al. 2007; Silvestrini et al. 2003 ] and onabotulinumtoxinA. The latter one is the only substance approved by the United States Food and Drug Administration (FDA) for prophylactic treatment of CM. Guidelines of the American Academy of Neurology state that onabotulinumtoxinA is effective and should be offered to patients with CM [Simpson et al. 2016 ].
In the UK the National Institute for Health and Care Excellence (NICE) recommends onabotuli-numtoxinA as a prophylactic treatment for CM in patients who did not respond to at least three prior pharmacologic prophylaxis therapies and whose condition is appropriately managed for medication overuse. According to NICE criteria, treatment with onabotulinumtoxinA should be stopped when patients do not respond to treatment adequately (defined as a reduction of monthly headache days of <30%) or when the patient's condition changes to EM (defined as a headache on <15 days per month in three consecutive months) [NICE, 2012] .
Mode of action of botulinum neurotoxin
Botulinum neurotoxin (BoNT) is a protein complex produced by the Gram-positive, anaerobic bacterium Clostridium botulinum. There are at least seven different BoNT serotypes, of which only two are currently in clinical use: BoNT serotype A and BoNT serotype B [Bigalke, 2013] .
After intramuscular or subcutaneous injection
BoNT is internalized into peripheral motor neurons via SV2 binding protein [Mahrhold et al. 2006 ]. Once translocated into the cytosol, BoNT enzymatically cleaves the 25 kDa synaptosomal-associated protein (SNAP-25), a protein, which mediates the fusion of neurotransmittercontaining vesicles with the cell membrane. Through this mechanism, BoNT inhibits the release of neurotransmitters from presynaptic nerve endings [Rummel, 2015] . This effect has been best studied for the suppression of acetylcholine release at the neuromuscular junction. However, more recent studies show that BoNT also modifies the release of neurotransmitters, which are relevant in the transduction of pain such as substance P Welch et al. 2000] or calcitonin gene-related peptide (GCRP) [Durham et al. 2004] . It is supposed that the inhibition of peripheral sensitization leads to an indirect inhibition of central sensitization and thus is a possible mechanism for the efficacy of BoNT in chronic pain [Aoki, 2003] . On the contrary, animal-model studies support the view, that there is a site for BoNT in the central nervous system, although the mechanisms of a central antinociceptive action of BoNT remain unclear [Matak and Lacković, 2014] . Research in this field is complicated by the absence of a widely accepted pathophysiological model for CM.
Clinical evidence
OnabotulinumtoxinA (Botox ® ) The analgesic effects of BoNT were observed 30 years ago in patients with Torticollis spasmodicus [Tsui et al. 1986 ]. This observation was attributed to the myorelaxant effects of BoNT. The first evidence for an effect of BoNT on migraine was found in patients who were treated with BoNT for hyperfunctional lines of the face. The first open-label, nonrandomized study enrolled a total of 106 patients. Of these 106 patients, 77 patients were classified as true migraineurs according to IHS criteria and received prophylactic treatment with onabotulinumtoxinA (Botox ® , Allergan Inc., Irvine, California, USA). Therapeutic benefit was measured by patients' self-reports. A total of 51% of the patients classified as having true migraine reported a complete response and 28%, a partial response [Binder et al. 2000 ].
The first placebo-controlled, double-blind study in migraine patients (2-8 migraine attacks per month) was carried out in the year 2000 with 123 patients. Participants were randomized into three groups and treated with either placebo, 25 or 75 mouse units (MU) onabotulinumtoxinA. The treatment with 25 MU onabotulinumtoxinA was found to be superior to placebo in the reduction of the number of monthly migraine attacks, whereas no differences could be identified between the 75 MU group and the placebo group [Silberstein et al. 2000 ].
In the following years, several subsequent studies failed to demonstrate positive effects on EM [Jackson et al. 2012 ] and tension headaches [Gaul et al. 2016 ]. For CM the results from controlled clinical trials were inconsistent.
In a placebo-controlled study conducted in 58 patients with chronic daily headache (CDH), onabotulinumtoxinA tended to improve the number of headache days in a 12-week period after injection, but missed the criteria for statistical significance [Ondo et al. 2004] . A multicentre study with 279 patients with CDH (three injection cycles) showed, that onabotulinumtoxinA increased the number of headache-free days in a 30-day period, but again differences between placebo and verum group were not statistically significant [Mathew et al. 2005] . A subgroup analysis of 228 patients without prophylactic medication at the date of study enrolment found a statistically significant difference in the number of headaches in a 30-day period. So the authors concluded that onabotulinumtoxinA was effective in the treatment of patients with CDH who do not receive other prophylactic medication ]. In another multicentre study 702 patients with CDH received three injection cycles with placebo or 75,175 or 225 MU onabotulinumtoxinA for 9 months. All groups responded to treatment, but the response was not superior to placebo . In 2007, a small, but double-blinded and placebo-controlled study with 32 participants failed to demonstrate a benefit for onabotulinumtoxinA in the prophylactic treatment of CM [Vo et al. 2007 ]. Freitag and colleagues treated 86 CM patients without medication overuse and found a statistically significant effect for onabotulinumtoxinA in the reduction of migraine episodes ]. An Italian doubleblind study with 68 patients with CM found no difference between onabotulinumtoxinA and placebo in the reduction of headache days, but was able to show, that treatment with onabotulinum-toxinA reduced the consumption of acute pain medication [Sandrini et al. 2011 ].
The breakthrough of onabotulinumtoxinA in the treatment of CM came in 2010, when the Phase III Research Evaluating Migraine Prophylaxis Therapy (PREEMPT) study group published the results of the PREEMPT I and PREEMPT II trial, in which a total of 1384 Patients were enrolled into both trials (PREEMPT I: 679, PREEMPT II: 705). Both studies consisted of a 28-day baseline screening period, a 24-week double-blind, parallel-group, placebo-controlled phase (two injection cycles) and a 32-week openlabel phase (three injection cycles). This pair of two multicentre randomized, placebo-controlled studies had an identical study design, but different endpoints.
In the PREEMPT I trial the primary endpoint reduction of migraine episodes was missed, but significant differences between the verum group and the placebo group were seen in the reduction of headache days and migraine days . The PREEMPT II trial confirmed the efficacy of onabotulinumtoxinA in the reduction of headache days as a primary endpoint [Diener et al. 2010] .
Until now there were only two studies comparing onabotulinumtoxinA with other drugs effective in the prophylactic treatment of CM. Magalhães and colleagues showed, that onabotulinumtoxinA was as effective as amitriptyline in the prophylactic treatment of CM [Magalhães et al. 2010 ], Cady and colleagues compared onabotulinum-toxinA with topiramate and found similar efficacy for the prophylactic treatment of CM [Cady et al. 2011] . Taking all evidence into consideration a meta-analysis stated in 2012, that Botulinum toxin A compared with placebo was associated with a small-to-moderate benefit for CM and CDH [Jackson et al. 2012] .
The positive results of the two PREEMPT trials led to the approval of onabotulinumtoxinA for the treatment of CM in September 2011 by the US FDA and subsequently many other registration authorities worldwide. After approval, various studies in real-life settings have been published on the use of onabotulinumtoxinA in CM. The results of these studies confirm the efficacy of onabotulinumtoxinA in CM [Cernuda-Morollón et al. 2014; Khalil et al. 2014; Russo et al. 2016] .
Because medication overuse is a major problem in CM patients, a separate view on this subgroup of patients might be helpful. Pooled data of both PREEMPT studies reveal that onabotulinumtox-inA is effective in the reduction of headache days in CM patients with concomitant medication overuse [Silberstein et al. 2013] . In a prospective study no difference between CM patients with medication overuse and CM patients without medication overuse could be found in terms of efficacy of onabotulinumtoxinA [Ahmed et al. 2015 ]. There might be indications that in CM patients with concomitant medication overuse, treatment with 195 MU is superior to treatment with 155 MU in the reduction of headache days, migraine days and days with medication intake .
Beside its effects on headache frequency and severity treatment with onabotulinumtoxinA also improves quality of life in Patients with CM. In the PREEMPT studies patients treated with onabotulinumtoxinA had a significant higher quality of life throughout the double-blind phase [Lipton et al. 2011 ] and the open-label phase [Lipton et al. 2016] .
Recently, a study from our centre confirmed these findings in a long-term real-life setting [Kollewe et al. 2016] . In this open-label study, 27 patients with CM received at least four injection cycles of onabotulinumtoxinA according to the PREEMPT injection paradigm. Monthly headache days, migraine days, days with nausea/vomiting and days with intake of pain medication were significantly reduced after the first treatment and this effect was stable throughout the entire study period. Furthermore, health-related quality of life and migraine-related quality of life improved after treatment with onabotulinumtoxinA. Patients were also screened for depression before the beginning of treatment and six weeks after every injection. Over the course of treatment patients had a significant decrease in depressive symptoms. In contrast with most of the studies mentioned previously, patients with severe depression were allowed to participate in this study. Theoretically the improvement of depression might be caused by the additional antidepressive action of BoNT [Finzi and Rosenthal, 2014; Magid et al. 2014; Wollmer et al. 2012 ].
In all of these studies a certain number of patients did not respond to treatment with onabotulinum-toxinA. Up to 10% of patients might be concerned with treatment failure during long-term treatment [Cernuda-Morollón et al. 2014] . Currently the development of antibodies, an intrinsic worsening of migraine or an initial placebo effect are discussed as reasons for the development of resistance to treatment with onabotulinumtoxinA [Cernuda-Morollón et al. 2014] .
In some studies, shorter duration of disease [Eross et al. 2005; Sandrini et al. 2011; Lee et al. 2016] , predominantly unilateral location of pain, presence of scalp allodynia, and pericranial muscle tenderness ] and increased interictal calcitonin gene-related peptide (CGRP) levels [Cernuda-Morollón et al. 2014 ] for a favourable outcome were observed. In a Korean study patients were screened with transcranial Doppler sonography. Patients with a higher ratio of the mean blood flow velocity in the middle cerebral artery to that of ipsilateral internal carotid artery were more likely to respond to treatment with onabotulinumtoxinA ]. However, reliable predictors and biomarkers for treatment response applicable in a real-world setting are lacking to date.
IncobotulinumtoxinA (Xeomin ® ) and abobotulinumtoxinA (Dysport ® )
OnabotulinumtoxinA is the only BoNT preparation, which has been approved for the treatment of CM. Until now no prospective trials using other BoNT preparations in patients with CM have been published. There is only one retrospective case series of 21 CM patients treated with incobotulinumtoxinA (Xeomin ® , Merz Pharmaceuticals GmbH, Frankfurt/M, Germany) [Kazerooni et al. 2015] . In this case series significant improvements in headache frequency and severity were observed under treatment with incobotulinumtoxinA.
AbobotulinumtoxinA
(Dysport ® , Beaufour Ipsen, Boulogne-Billancourt, France) has been investigated in patients with EM, but no significant effects on the frequency and severity of headache were found [Petri et al. 2009 ]. To the best of our knowledge to date no data are available for the use of abobotulinumtoxinA in patients with CM.
Doses and injection sites
The first studies with BoNT injections in headache and migraine used a variety of different dosages, concentrations and injection sites for BoNT. In 2010 the PREEMPT study group developed an injection paradigm based on various studies conducted in patients with EM, CM and tensiontype headaches. The PREEMPT injection paradigm combines two different approaches for the injection of BoNT in migraine: fixed injections sites and follow the pain injection sites. Fifty MU of onabotulinumtoxinA are diluted with 2.0 ml of saline, yielding a concentration of 5 MU/0.1 ml. Each intramuscular injection site is injected with 5 MU onabotulinumtoxinA. The injection paradigm consists of 31 fixed sites in the following muscles: mm. frontalis 20 MU (four sites), mm. corrugatores 10 MU (two sites), m. procerus 5 MU (1 site), mm. occipitalis 30 MU (six sites), mm. temporalis 40 MU (eight sites), mm. trapezii 30 MU (in six sites), cervical paraspinal muscle group 20 MU (four sites). In these fixed sites a total dose of 155 MU onabotulinumtoxinA is applied. Additional 40 MU can be administered into temporalis (two sites), occipitalis (two sites) or trapezius muscles (four sites), receiving a maximum of 195 MU [Blumenfeld et al. 2010] .
Little is known about the duration of analgesic effects of onabotulinumtoxinA. It is supposed, that it is similar to the duration of its myorelaxant effects. Therefore most studies used a fixed treatment interval of 12 weeks for onabotulinumtox-inA injections. Clinical experience in the use of BoNT for other neurologic indications shows, that it might be useful to adapt treatment intervals individually to the patients' needs [Dressler et al. 2015] . However shorter treatment intervals go along with an increased risk of antibody formation against BoNT resulting in treatment failure [Lange et al. 2009 ].
Safety and tolerability
Adverse effects (AEs) of BoNT are usually related to the injection, systemic AEs are very rare [Silberstein, 2016] . Injection-related AEs are usually mild and transient and rarely lead to abortion of therapy. Among the reported AEs in the PREEMPT studies, neck pain (4.3%), injection site pain (2.1%), eyelid ptosis (1.9%), muscular weakness (1.6%) were most common [Aurora et al. 2014] . Data from various clinical studies document that treatment with onabotuli-numtoxinA is tolerable [Cernuda-Morollón et al. 2014; Kollewe et al. 2016; Silberstein et al. 2005] .
Conclusion
OnabotulinumtoxinA is the substance that has been best studied in the prophylactic treatment of CM. There is good clinical evidence that treatment with onabotulinumtoxinA leads to a reduction of monthly headache days and improves quality of life. Treatment with onabotulinumtox-inA is well tolerated by the patients. Further research is needed to elucidate the analgesic mechanism of onabotulinumtoxinA in CM.
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